Tuesday, Sept 10th Press Briefing

Moderator: Toni Rosell/Webcasts at bottom of page

  • Summary of day’s plenary (5 mins) and any key highlights/themes
  • KEYNOTE-024 3-Year Survival Update: Pembrolizumab vs Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer -- M. Reck
  • IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC -- F. Cappuzzo
  • Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC-- S. Gettinger
  • Challenges in Lung Cancer Clinical Trials: A European Perspective -- A.M. Baird
  • PL 03: Establishing a Nurse Led Follow-Up Service for Patients With Resected Early Stage Lung Cancer   -- J. Mitchell
 

Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

(Summary and slides from the Press Briefing presentation and submitted abstract)

pictures drag to desctop and enlarge

Presenting Author @ press conference: Scott Gettinger